266 related articles for article (PubMed ID: 10221570)
1. Neuroendocrine differentiation in prostatic carcinoma.
Abrahamsson PA
Prostate; 1999 May; 39(2):135-48. PubMed ID: 10221570
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine cells in tumour growth of the prostate.
Abrahamsson PA
Endocr Relat Cancer; 1999 Dec; 6(4):503-19. PubMed ID: 10730904
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine pathogenesis in adenocarcinoma of the prostate.
Hansson J; Abrahamsson PA
Ann Oncol; 2001; 12 Suppl 2():S145-52. PubMed ID: 11762343
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation and hormone-refractory prostate cancer.
Abrahamsson PA
Prostate Suppl; 1996; 6():3-8. PubMed ID: 8630226
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine differentiation in prostatic malignancy.
di Sant'Agnese PA; Cockett AT
Cancer; 1996 Jul; 78(2):357-61. PubMed ID: 8674017
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications.
di Sant'Agnese PA
Cancer; 1992 Jul; 70(1 Suppl):254-68. PubMed ID: 1350941
[TBL] [Abstract][Full Text] [Related]
10. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
Bonkhoff H; Fixemer T
Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment.
Jiborn T; Bjartell A; Abrahamsson PA
Urology; 1998 Apr; 51(4):585-9. PubMed ID: 9586611
[TBL] [Abstract][Full Text] [Related]
12. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
[TBL] [Abstract][Full Text] [Related]
13. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
14. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine differentiation in prostatic carcinoma: an update.
di Sant'Agnese PA
Prostate Suppl; 1998; 8():74-9. PubMed ID: 9690666
[TBL] [Abstract][Full Text] [Related]
16. The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research.
Di Sant'Agnese PA; Cockett AT
J Urol; 1994 Nov; 152(5 Pt 2):1927-31. PubMed ID: 7933249
[TBL] [Abstract][Full Text] [Related]
17. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
18. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
Matsumoto Y; Mibu H; Kagebayashi Y
Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
20. [Neuroendocrine differentiation in adenocarcinoma of the prostate with progression of disease during hormonal treatment: a report of two cases].
Kosugi M; Hanawa Y; Momma T; Saito S; Hirose S
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):521-4. PubMed ID: 12795167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
